Levosimendan Waymade (Levosimendan)

The drug binds to cardiac troponin C, which raises the sensitivity of the contractile proteins to existing calcium, enhancing heart‑muscle contraction without raising intracellular calcium levels. At the same time it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous dilation that reduces preload and afterload.

The dosing regimen is determined by the prescribing clinician based on the patient’s clinical status, weight, and renal function. The prescriber selects the appropriate infusion rate and duration, following local guidelines and the product’s prescribing information.

The safety of Levosimendan during pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Unlike traditional catecholamine inotropes, Levosimendan increases contractility without markedly raising intracellular calcium, which may reduce the risk of arrhythmias. Its combined vasodilatory effect also lowers afterload, offering a dual mechanism that can be advantageous over agents that act solely as pure inotropes.

The injectable solution must be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the administration protocol.

Levosimendan is given as an intravenous infusion, typically via a controlled infusion pump. The drug is administered over a prescribed period, often starting with a loading dose followed by a maintenance infusion, under continuous cardiovascular monitoring in a hospital setting.

The most critical adverse events include severe hypotension, which can lead to organ hypoperfusion, and life‑threatening tachyarrhythmias such as sustained ventricular tachycardia. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised, and it may be avoided, in individuals with severe hypotension, uncontrolled arrhythmias, or those receiving strong vasodilators that could precipitate dangerous blood‑pressure drops.